SCHEMBL23200315

SCHEMBL23200315

CCOC(=O)c1cc(C)ccc1NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.76
▸ KMT2A Q03164 2/20 0.64
▸ TSHR P16473 2/20 0.64
▸ ALDH1A1 P00352 4/20 0.60
▸ KDM4E B2RXH2 3/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ HTT P42858 2/20 0.60
▸ GAA P10253 2/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ TP53 P04637 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ METAP2 P50579 3/20 0.59
▸ MAPT P10636 2/20 0.55
▸ RXFP1 Q9HBX9 1/20 0.54
▸ RECQL P46063 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31138238 1.00 LMNA (0.76) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL7667611 0.86 LMNA (0.64) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL12570805 0.81 METAP2 (0.86) LMNAHTTL3MBTL1TDP1METAP2
SCHEMBL14855615 0.80 LMNA (0.86) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL28572592 0.80 MAPT (0.65) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL13034754 0.79 FFAR4 (0.60) LMNAKMT2AKDM4EHTTGAA
SCHEMBL1071830 0.79 CYP2C9 (0.79) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL3511869 0.78 FFAR4 (0.62) LMNAKMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL19436594 0.78 CYP1A2 (0.54) LMNAKMT2ATSHRALDH1A1KDM4E
SCHEMBL13034765 0.78 LMNA (0.60) LMNAKMT2ATSHRKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 — — US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 — — EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 — — EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 — — US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 — — EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 — — US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB LMNA 1478/4885KMT2A 2984/4885TSHR 4310/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB LMNA 1478/4885KMT2A 2984/4885TSHR 4310/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB LMNA 1478/4885KMT2A 2984/4885TSHR 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback